Compare BHVN & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHVN | PGY |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2022 | 2021 |
| Metric | BHVN | PGY |
|---|---|---|
| Price | $14.03 | $18.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | $21.27 | ★ $28.82 |
| AVG Volume (30 Days) | ★ 2.5M | 2.0M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.08 | ★ 116.43 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $1,301,360,000.00 |
| Revenue This Year | N/A | $12.32 |
| Revenue Next Year | N/A | $16.33 |
| P/E Ratio | ★ N/A | $24.91 |
| Revenue Growth | N/A | ★ 26.07 |
| 52 Week Low | $7.48 | $10.40 |
| 52 Week High | $18.57 | $31.06 |
| Indicator | BHVN | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 52.56 |
| Support Level | $13.56 | $16.28 |
| Resistance Level | $15.27 | $19.09 |
| Average True Range (ATR) | 0.81 | 1.01 |
| MACD | 0.32 | 0.27 |
| Stochastic Oscillator | 56.59 | 85.99 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.